Upland

Running trials

• Recruiting

  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  NCT06764875· Phase 3· Source

• Recruiting

  A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

  NCT06830629· Phase 2· Source

• Active, not recruiting

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· Phase 3· Source

• Active, not recruiting

  Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

  NCT05138133· Phase 3· Source

• Active, not recruiting

  Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

  NCT04877691· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Gastric and esophageal cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)

  NCT04609878· Phase 3· Source

• Completed

  Tezepelumab COPD Exacerbation Study

  NCT04039113· Phase 2· Source